Test-retest reliability of the CSV-1000 contrast test and its relationship to glaucoma therapy
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Test-retest reliability of the CSV-1000 contrast test and its relationship to glaucoma therapy

Pomerance GN;Evans DW;;
investigative ophthalmology & visual science 1994 Vol. 35 pp. -
268
gn1994investigativetest-retest

Abstract

Visual function in patients with glaucoma, as measured by contrast sensitivity, does improve after beta-blocker therapy. Further, the CSV-1000 is a clinically reliable tool for monitoring these changes.

Keywords

National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine reproducibility of results contrast sensitivity / physiology* aged middle aged Retrospective Studies vision pmid:8056510 g n pomerance d w evans betaxolol / therapeutic use glaucoma open-angle / drug therapy* open-angle / physiopathology levobunolol / therapeutic use timolol / therapeutic use vision disorders / diagnosis* vision tests* ocular

Access

URL:
http://www.ncbi.nlm.nih.gov/pubmed/8056510

Citation

ID: 115324
Ref Key: gn1994investigativetest-retest
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
115324
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store